Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene

• US 20120164641A1
• Filed: 12/13/2011
• Published: 06/28/2012
• Est. Priority Date: 12/22/2010
• Status: Abandoned Application

• Current Assignee: Roche Molecular Systems (Roche Holding AG)
• Original Assignee: Roche Molecular Systems (Roche Holding AG)
• Inventors: Bauer, Keith, Schoenbrunner, Nancy, Tsan, Alison
• Application Number:
  US13/324,705
• Publication Number:
  US 20120164641A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The invention comprises reagents and methods for detecting cancer-causing mutations in the human EGFR gene. Further, a method of detecting the mutations and a method of treatment are disclosed.

Claims

1. An oligonucleotide comprising the primary sequence of oligonucleotides selected from SEQ ID NOs. 2, 10, 18, 27, 32, 51, 60, 71, 82, 93 and 104.

2. The oligonucleotide according to claim 1, further comprising at least one additional mismatch with the corresponding portion of SEQ ID NO:

1.

3. The oligonucleotide according to claim 1, further comprising at least one nucleotide with a base modified at the exocyclic amino group.

4. The oligonucleotide according to claim 3, wherein the nucleotide with a base modified at the exocyclic amino group is selected from tert-butyl-benzyl-deoxyadenine, tert-butyl-benzyl-deoxycytosine, methyl-deoxyadenine, methyl-deoxyxytosine, ethyl-deoxyadenine and ethyl-deoxycytosine.

9. A method of detecting mutations in the human epidermal growth factor receptor (EGFR) nucleic acid in a sample comprising:

(a) contacting the nucleic acid in the sample with the oligonucleotide of claim 1;

(b) incubating the sample under conditions allowing hybridization of the oligonucleotide to the target sequence within the EGFR nucleic acid;

(c) generating of the amplification product containing the target sequence within the EGFR nucleic acid; and

(d) detecting the presence of the amplified product thereby detecting the presence of the mutation in the EGFR nucleic acid.

10. The method of claim 9, wherein the nucleic acid in the sample is contacted with the oligonucleotide of claim 1.

11. The method of claim 9, wherein the amplification is performed by real-time PCR.

12. A method of determining whether a patient having a malignant tumor is likely to respond to EGFR inhibitors, comprising:

(a) contacting the nucleic acid in the sample from the patient with the oligonucleotide of claim 1;

(b) incubating the sample under conditions allowing hybridization of the oligonucleotide to the target sequence within the EGFR nucleic acid; and

generation of the amplification product containing the target sequence within the EGFR nucleic acid;

(c) detecting the presence of the amplified product thereby detecting the presence of the mutation in the EGFR nucleic acid, wherein the presence of the mutation indicates that the patient is likely to respond to EGFR inhibitors.

13. The method of claim 12, wherein the amplification in step (b) and detection in step (c) are performed by real-time PCR.

14. The method of claim, 12 wherein said EGFR inhibitor is cetuximab, panitumumab, erlotinib or gefitinib.

5. An oligonucleotide selected from SEQ ID NOs. 3-7, 11-15, 19-24, 28, 29, 33-48, 52-57, 61-68, 72-79, 83-90, 94-101, 105 and 106.

6. An oligonucleotide selected from SEQ ID NOs. 8, 16, 25, 30, 49, 58, 69, 80, 91, 102 and 107.

7. An oligonucleotide selected from SEQ ID NOs. 9 and 109, 17 and 110, 26 and 111, 31 and 112, 50 and 113, 59 and 114, 70 and 115, 81 and 116, 92 and 117, 103 and 118 and 108 and 119.

8. The oligonucleotide according to claim 7, further comprising a detectable label.

15. A kit for detecting mutations in the human epidermal growth factor receptor (EGFR) gene comprising one or more pairs of oligonucleotides selected from pairs (a)-(k):

(a) an oligonucleotide of one of SEQ ID NOs;

2-7 and the oligonucleotide of SEQ ID NO;

8;

(b) an oligonucleotide of one of SEQ ID NOs;

10-15 and the oligonucleotide of SEQ ID NO;

16;

(c) an oligonucleotide of one of SEQ ID NOs;

18-24 and the oligonucleotide of SEQ ID NO;

25;

(d) an oligonucleotide of one of SEQ ID NOs;

27-29 and the oligonucleotide of SEQ ID NO;

30;

(e) an oligonucleotide of one of SEQ ID NOs;

32-48 and the oligonucleotide of SEQ ID NO;

49;

(f) an oligonucleotide of one of SEQ ID NOs;

51-57 and the oligonucleotide of SEQ ID NO;

58;

(g) an oligonucleotide of one of SEQ ID NOs;

60-68 and the oligonucleotide of SEQ ID NO;

69;

(h) an oligonucleotide of one of SEQ ID NOs;

71-79 and the oligonucleotide of SEQ ID NO;

80;

(i) an oligonucleotide of one of SEQ ID NOs;

82-90 and the oligonucleotide of SEQ ID NO;

91;

(j) an oligonucleotide of one of SEQ ID NOs;

93-101 and the oligonucleotide of SEQ ID NO;

102;

(k) an oligonucleotide of one of SEQ ID NOs;

104-106 and the oligonucleotide of SEQ ID NO;

107.

16. The kit of claim 15, further comprising an additional oligonucleotide as follows:

the kit with the pair of oligonucleotides (a) further comprising the oligonucleotide of SEQ ID NOS 9 and 109;

the kit with the pair of oligonucleotides (b) further comprising the oligonucleotide of SEQ ID NOS 17 and 110;

the kit with the pair of oligonucleotides (c) further comprising the oligonucleotide of SEQ ID NOS 26 and 111;

the kit with the pair of oligonucleotides (d) further comprising the oligonucleotide of SEQ ID NOS 31 and 112;

the kit with the pair of oligonucleotides (e) further comprising the oligonucleotide of SEQ ID NOS 50 and 113;

the kit with the pair of oligonucleotides (f) further comprising the oligonucleotide of SEQ ID NOS 59 and 114;

the kit with the pair of oligonucleotides (g) further comprising the oligonucleotide of SEQ ID NOS 70 and 115;

the kit with the pair of oligonucleotides (h) further comprising the oligonucleotide of SEQ ID NOS 81 and 116;

the kit with the pair of oligonucleotides (i) further comprising the oligonucleotide of SEQ ID NOS 92 and 117;

the kit with the pair of oligonucleotides (j) further comprising the oligonucleotide of SEQ ID NOS 103 and 118;

the kit with the pair of oligonucleotides (k) further comprising the oligonucleotide of SEQ ID NOS 108 and 119.

17. The kit of claim 15, wherein said additional oligonucleotide is labeled.

18. The kit of claim 15, further comprising nucleoside triphosphates, nucleic acid polymerase and buffers necessary for the function of the nucleic acid polymerase.

19. A reaction mixture for detecting mutations in the human epidermal growth factor receptor (EGFR) gene comprising one or more pairs of oligonucleotides selected from pairs (a)-(k):

an oligonucleotide of one of SEQ ID NOs;

2-7 and the oligonucleotide of SEQ ID NO;

8;

an oligonucleotide of one of SEQ ID NOs;

10-15 and the oligonucleotide of SEQ ID NO;

16;

an oligonucleotide of one of SEQ ID NOs;

18-24 and the oligonucleotide of SEQ ID NO;

25;

an oligonucleotide of one of SEQ ID NOs;

27-29 and the oligonucleotide of SEQ ID NO;

30;

an oligonucleotide of one of SEQ ID NOs;

32-48 and the oligonucleotide of SEQ ID NO;

49;

an oligonucleotide of one of SEQ ID NOs;

51-57 and the oligonucleotide of SEQ ID NO;

58;

an oligonucleotide of one of SEQ ID NOs;

60-68 and the oligonucleotide of SEQ ID NO;

69;

an oligonucleotide of one of SEQ ID NOs;

71-79 and the oligonucleotide of SEQ ID NO;

80;

an oligonucleotide of one of SEQ ID NOs;

82-90 and the oligonucleotide of SEQ ID NO;

91;

an oligonucleotide of one of SEQ ID NOs;

93-101 and the oligonucleotide of SEQ ID NO;

102;

an oligonucleotide of one of SEQ ID NOs;

104-106 and the oligonucleotide of SEQ ID NO;

107.

20. The reaction mixture of claim 22, further comprising an additional oligonucleotide as follows:

the reaction mixture with the pair of oligonucleotides (a) further comprising the oligonucleotide of SEQ ID NOS 9 and 109;

the reaction mixture with the pair of oligonucleotides (b) further comprising the oligonucleotide of SEQ ID NOS 17 and 110;

the reaction mixture with the pair of oligonucleotides (c) further comprising the oligonucleotide of SEQ ID NOS 26 and 111;

the reaction mixture with the pair of oligonucleotides (d) further comprising the oligonucleotide of SEQ ID NOS 31 and 112;

the reaction mixture with the pair of oligonucleotides (e) further comprising the oligonucleotide of SEQ ID NOS 50 and 113;

the reaction mixture with the pair of oligonucleotides (f) further comprising the oligonucleotide of SEQ ID NOS 59 and 114;

the reaction mixture with the pair of oligonucleotides (g) further comprising the oligonucleotide of SEQ ID NOS 70 and 115;

the reaction mixture with the pair of oligonucleotides (h) further comprising the oligonucleotide of SEQ ID NOS 81 and 116;

the reaction mixture with the pair of oligonucleotides (i) further comprising the oligonucleotide of SEQ ID NOS 92 and 117;

the reaction mixture with the pair of oligonucleotides (j) further comprising the oligonucleotide of SEQ ID NOS 103 and 118;

the reaction mixture with the pair of oligonucleotides (k) further comprising the oligonucleotide of SEQ ID NOS 108 and 119.